New Clot-Busting drug passes first safety check in healthy people
NCT ID NCT06665828
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This early-stage study tested a single dose of REGN9533 in 72 healthy adults to see if it is safe and how the body handles it. Researchers measured side effects, drug levels in the blood, and whether the body made antibodies against the drug. The goal is to gather safety data before testing REGN9533 in people with blood-clotting diseases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SGS Belgium NV_Edegem
Edegem, Antwerp, 2650, Belgium
Conditions
Explore the condition pages connected to this study.